Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Shares Outstanding (2016 - 2018)

BeOne Medicines (BEIGF) has disclosed Shares Outstanding for 4 consecutive years, with $776.3 million as the latest value for Q4 2018.

  • Quarterly Shares Outstanding rose 31.11% to $776.3 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $776.3 million through Dec 2018, up 31.11% year-over-year, with the annual reading at $776.3 million for FY2018, 31.11% up from the prior year.
  • Shares Outstanding for Q4 2018 was $776.3 million at BeOne Medicines, up from $701.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $776.3 million in Q4 2018, with the low at $116.2 million in Q4 2015.
  • Average Shares Outstanding over 4 years is $526.0 million, with a median of $518.8 million recorded in 2017.
  • The sharpest move saw Shares Outstanding surged 344.02% in 2016, then rose 14.78% in 2017.
  • Over 4 years, Shares Outstanding stood at $116.2 million in 2015, then surged by 344.02% to $515.8 million in 2016, then rose by 14.78% to $592.1 million in 2017, then surged by 31.11% to $776.3 million in 2018.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $776.3 million, $701.6 million, and $698.9 million for Q4 2018, Q2 2018, and Q1 2018 respectively.